NCT06377345 Remote Patient Monitoring Solution for Chronic Respiratory Disease Management
| NCT ID | NCT06377345 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SingHealth Polyclinics |
| Condition | Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-05-01 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2024-05-01 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation. Methodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited. Importance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation. Potential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of asthma * Pediatric patients (age 7 to 17), adult patients (age 18 and above * Have an asthma exacerbation on the day of visit * Be willing to use the AeviceMD device * Has a smart phone to download the application that is paired with Aevice * Has wireless fidelity (WIFI) connection to use with Aevice * English speaking Exclusion Criteria: * No capacity for consent * Concurrent chronic obstructive pulmonary disease (COPD)
Contact & Investigator
Mabel QH Leow, PhD
PRINCIPAL INVESTIGATOR
SingHealth Polyclinics
Frequently Asked Questions
Who can join the NCT06377345 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 90 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06377345 currently recruiting?
Yes, NCT06377345 is actively recruiting participants. Contact the research team at mabel.leow.q.h@singhealth.com.sg for enrollment information.
Where is the NCT06377345 trial being conducted?
This trial is being conducted at Singapore, Singapore.
Who is sponsoring the NCT06377345 clinical trial?
NCT06377345 is sponsored by SingHealth Polyclinics. The principal investigator is Mabel QH Leow, PhD at SingHealth Polyclinics. The trial plans to enroll 180 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.